This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued strength across its business segments.
Quest Diagnostics (DGX) Q3 Earnings Top Estimates, View Up
by Zacks Equity Research
Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.
Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 33.78% and 12.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Quest Diagnostics (DGX) Ahead of Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ResMed (RMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).
QIAGEN (QGEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.
Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow
by Zacks Equity Research
Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.
Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Enhances Lab Experience With Facility
by Zacks Equity Research
Quest Diagnostics (DGX) new facility is fully operational and will empower better health for the patients and clients in the seven states the lab serves.
COVID Test Demand to Aid Quest Diagnostics (DGX) Q3 Earnings
by Zacks Equity Research
In terms of strategic acquisitions, Quest Diagnostics (DGX) is likely to have secured high returns in Q3 from the acquisition of Mercy's outreach laboratory services business.
The Zacks Analyst Blog Highlights: Abbott Laboratories, UnitedHealth, Quest, and West Pharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, UnitedHealth, Quest, and West Pharmaceutical
Growing COVID-19 Testing Demand to Boost Abbott's (ABT) Q3 Earnings
by Zacks Equity Research
Through July to September, Abbott's (ABT) Diagnostic business is likely to have benefited from the significant surge in the new COVID-19 case counts.
Thermo Fisher (TMO) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher's (TMO) recent launches within Chromatography and Mass Spectrometry like Thermo Scientific Orbitrap IQ-X Tribrid Mass Spectrometer should have contributed to its Q3 top line.
Zacks.com featured highlights include: Hibbett, O'Reilly Automotive, The Interpublic Group of Companies and Quest Diagnostics
by Zacks Equity Research
Zacks.com featured highlights include: Hibbett, O'Reilly Automotive, The Interpublic Group of Companies and Quest Diagnostics
4 Stocks That Stand Out on Attractive Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Hibbett (HIBB), O'Reilly Automotive (ORLY), The Interpublic Group of Companies (IPG) and Quest Diagnostics (DGX) are sound enough to meet financial obligations.
5 Finest PEG Stocks Based on Hybrid Investment Strategy
by Urmimala Biswas
Here are five out of the 14 stocks, TSCDY, REGN, DGX, EQNR and MAKSY that qualified the screening.
Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities
by Zacks Equity Research
Quest Diagnostics' (DGX) efforts to support AHA will boost innovative solutions like the Scholars programs, hypertension control and COVID-19 rapid response.
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Faster adoption of digital health and an improved business environment are expected to have contributed to Walgreens' (WBA) fourth-quarter performance.
Down 9.4% in 4 Weeks, Here's Why Quest Diagnostics (DGX) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Quest Diagnostics (DGX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers
by Zacks Equity Research
Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).
3 High-Potential MedTech Stocks With More Than 50% Growth YTD
by Riya Anand
Stocks like West Pharmaceuticals Services (WST), Maravai LifeSciences (MRVI) and Option Care Health (OPCH) have gained stupendously year to date.
Here's Why You Should Invest in Quest Diagnostics (DGX) Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) backed by its strong second-quarter performance and recovery in the base testing business.
Zacks Industry Outlook Highlights: Encompass Health, RadNet, U.S. Physical Therapy and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Encompass Health, RadNet, U.S. Physical Therapy and Quest Diagnostics
3 Top Stocks From the Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. EHC, RDNT and USPH are well-poised to gain from the prospects.